AbbVie faces hepatitis C patent challenge in India
26-07-2018
Public interest group challenges ‘unmerited’ Gilead patents
26-10-2017
Hailshadow / iStockphoto.com
India-based Initiative for Medicines, Access & Knowledge (I-MAK) has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
patent, hepatitis C, affordable treatment, patent challenges, generics, MSF, Médecins Sans Frontières, sofosbuvir, daclatasvir, velpatasvir
